Biotransformation of the antipsychotic agent, mazapertine, in dog - Mass spectral characterization and identification of metabolites

Xenobiotica

Volumn 29, Issue 5, 1999, Pages 453-466

  Wu, W N ^a   McKown, L A ^a   Takacs, A R ^a   Jones, W J ^a   Reitz, A B ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MAZAPERTINE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEALKYLATION; DOG; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG FECES LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; RADIOACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DOGS; FECES; FEMALE; MALE; MASS SPECTROMETRY; PIPERAZINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033054958     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238470     Document Type: Article

References (8)

1. BUCLIN, T., STUCKI, R., JAQUET-MUELLER, F., MUNAFO, A., BAULDAUF, C., BRUNNER-FERBER, F. and BIOLLAZ, J., 1993a, Tolerability and psychopharmacological profile of the novel antipsychotic mazapertine (RWJ-37796) in healthy volunteers. Clinical Pharmacology and Therapeutics, 53, 179 (abstract, 94th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics).
2. BUCLIN, T., STUCKI, R., JAQUET-MUELLER, F., MUNAFO, A., BAULDAUF, C., BRUNNER-FERBER, F., PIQUET, V. and BIOLLAZ, J., 1993b, Tolerance, psychopharmacological profile and pharmacokinetics of a new neuroleptic, mazapertine (RWJ-37796), in healthy volunteers. Schweizerische Medizinische Wochenschrift, 123 (16, S50), 39.
3. GISCLON, L. G. and CURTIN, C.R., 1993, The effect of food on the bioavailability (BA) of a new antipsychotic drug (RWJ-37796). Pharmaceutical Research, 10, S-398 (abstract, AAPS 8th Annual Meeting).
4. 1A-adrenergic affinity and a low potential for extrapyramidal effects. Journal of Medicinal Chemistry, 37, 1060-1062.
5. REITZ, A. B., MCDONNELL, M. E., BAXTER, E. W., CODD, E. E. and WU, W. N., 1997, The synthesis and evaluation of the major metabolites of mazapertine. Bioorganic and Medicinal Chemistry Letters, 7, 1927-1930.
6. WONG, D. F., YUNG, B. C. K., GIORGIANNI, J. A., CHEN, C., CHAN, B., GISCLON, L. G., DANNALS, R. F., RAVERT, H. T., SHAYA, E., CURTIN, C. R. and OFFORD, S. J., 1993, D2 Dopamine receptor occupancy as a function of intravenous rising dose of mazapertine (RWJ-37796) in normal living human brain. Journal of Nuclear Medicine, 34, 109 (abstract, 40th Annual Meeting of the Society of Nuclear Medicine).
7. WU, W. N., MCKOWN, L. A., GAUTHIER, A. D., JONES, W. J. and TAKACS, A. R., 1994a, Metabolism and excretion of the antipsychotic agent, RWJ-3776 in rats, Pharmaceutical Research, 11, S-336 (abstract, the 9th AAPS Annual Meeting).
8. WU, W. N., MCKOWN, L. A., JONES, W. J., TAKACS, A. R., REITZ, A. B. and MCDONNELL, M. E., 1994b, Mass spectral characterization and identification of the metabolites of the antipsychotic agent, RWJ-37796, in dogs. Proceedings of the 42nd ASMS Conference on Mass Spectrometry, 344.